Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > SBM tweeting up a storm

<< Previous

Bullboard Posts

Next >>

Comment by Pareto8020on Apr 12, 2021 2:04pm

143 Views

Post# 32978468

RE:SBM tweeting up a storm

The price action lately doesn't point to a company on the verge of announcing:

- Phase I clinical trial results for their SGLT2 which from CEO comments have been proceeding very well.

- Contract with 2 majors in animal pharma for SBM's SGLT2 compound.

- TFC1067 contracts for standard and higher dose concentration.

- Moving to clinical trials for their Botox killer compound.

Hopefully SBM with CURE's assistance can catch the market by surprise with a contract announcement and draw some new investors into the fold.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project